MedPath

POSTERIOR SUB-TENON'S Avastin

Phase 4
Withdrawn
Conditions
Diffuse Diabetic Macular Edema
Registration Number
NCT00567372
Lead Sponsor
Asociación para Evitar la Ceguera en México
Brief Summary

Posterior sub-tenon's injection of bevacizumab decreased diffuse diabetic macular edema

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Patients with diffuse diabetic macular edema non-proliferative diabetic retinopathy Maculat thickness ≥250 μ BCVA ≥ 20/400 Without any treatment

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
macular volumebaseline, 3,6 and 12 weeks
Secondary Outcome Measures
NameTimeMethod
macular thicknessbaseline,3,6 and 12 weeks
best corrected visual acuitybaseline, 3,6 and 12 weeks

Trial Locations

Locations (1)

Asociación para Evitar la Ceguera en Mexico

🇲🇽

Mexico DF, DF, Mexico

© Copyright 2025. All Rights Reserved by MedPath